公司概覽
業務類別 Drug Manufacturers - General
業務概覽 Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introducedits first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgenalso has a growing biosimilar portfolio.
公司地址 One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
電話號碼 +1 805 447-1000
傳真號碼 +1 805 447-1010
公司網頁 https://www.amgen.com
員工數量 31500
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Robert A. Bradway Chairman of the Board, President and Chief Executive Officer 美元 1.87M 13/02/2026
Mr. Jonathan P. Graham Executive Vice President, General Counsel and Secretary -- 13/02/2026
Mr. Murdo Gordon Executive Vice President, Global Commercial Operations 美元 1.20M 13/02/2026
Mr. Esteban Santos Executive Vice President, Operations -- 13/02/2026
Mr. Matthew C. Busch Vice President, Finance and Chief Accounting Officer -- 13/02/2026
Dr. David M. Reese, M.D. Executive Vice President and Chief Technology Officer 美元 1.27M 13/02/2026
Mr. Peter H. Griffith Executive Vice President and Chief Financial Officer 美元 1.13M 13/02/2026
Ms. Nancy A. Grygiel Senior Vice President and Chief Compliance Officer -- 13/02/2026
Mr. Derek Miller Senior Vice President, Human Resources -- 13/02/2026
Dr. James E. Bradner, M.D. Executive Vice President, Research and Development 美元 1.21M 13/02/2026
Ms. Rachna Khosla Senior Vice President, Business Development -- 13/02/2026
 
董事會成員
董事會 職務 更新日期
Ms. Amy E. Miles Independent Director 13/02/2026
Mr. Charles M. Holley, Jr Independent Director 13/02/2026
Ms. Ellen J. Kullman Independent Director 13/02/2026
Mr. Robert A. Eckert Lead Independent Director 13/02/2026
Mr. Robert A. Bradway Chairman of the Board, President and Chief Executive Officer 13/02/2026
Professor Dr. Tyler E. Jacks, PhD Independent Director 13/02/2026
Mr. Greg C. Garland Independent Director 13/02/2026
Dr. Wanda M. Austin Independent Director 13/02/2026
Dr. Brian J. Druker, M.D. Independent Director 13/02/2026
Mr. Michael V. Drake Independent Director 13/02/2026
Dr. S. Omar Ishrak Independent Director 13/02/2026
Ms. Mary E. Klotman Independent Director 13/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:24)
代號 名稱 佔比% 持有日期
JDOCJPMorgan Healthcare Leaders ETF<0.000001%01/10/2025
KATScharf ETF<0.000001%29/08/2025
KVLEKraneShares Value Line® Dyn Div Eq ETF<0.000001%12/01/2026
LOGOAlpha Brands Consumption Leaders ETF<0.000001%02/01/2026
LRGEClearBridge Large Cap Growth Select ETF<0.000001%27/02/2026
LRNDNYLI U.S. Large Cap R&D Leaders ETF<0.000001%28/08/2025
LVHDFranklin U.S. Low Volatility Hi Div ETF<0.000001%27/02/2026
MKTNFederated Hermes MDT Market Neutral ETF<0.000001%14/02/2026
MOTEVanEck Morningstar ESG Moat ETF<0.000001%16/09/2025
NUDVNuveen ESG Dividend ETF<0.000001%27/08/2025
NULVNuveen ESG Large-Cap Value ETF<0.000001%02/06/2025
PALCPacer Lunt Large Cap Mlt Ftr Alt ETF<0.000001%27/02/2026
QARPXtrackers Russell 1000 US QARP ETF<0.000001%30/06/2025
QFLRInnovator Nasdaq-100 Managed Floor ETF<0.000001%15/08/2025
QQLVInvesco QQQ Low Volatility ETF<0.000001%22/09/2025
RAFEPIMCO RAFI ESG US ETF<0.000001%22/12/2025
RALSProShares RAFI® Long/Short<0.000001%30/04/2022
RCGERockCreek Global Equality ETF<0.000001%26/09/2025
RWLCRayliant Wilshire NxtGen US Lg Cp Eq ETF<0.000001%05/06/2025
SAWGAAM Sawgrass U.S. Lg Cp Qual Gr ETF<0.000001%08/09/2025
  1    2    3    4    5    6    7    8    9    10    11    12    13    14    15    16    17    18    19   20    21    22  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.